In-Vivo CD19 Competitive Map: 91 Programs Across 71 Companies

We mapped 91 programs across 71 companies, academic institutions and hospitals by therapeutic area, highest phase of development and single vs. multi-target strategies.

CD19 + BCMA is still the center of gravity amongst multi-target approaches, but single-target programs still matter. CD19 alone is a B-cell reset story, while BCMA adds long-lived plasma cells that can escape CD19-only treatment. This has utility across oncology and autoimmune disease. But broader depletion needs to earn its place. If CD19 alone can deliver durable remission with a cleaner safety profile, then adding another target may offer only incremental value. Separately, the platform approach (linear mRNA/tLNPs, circular RNA/tLNPs, or targeted lentiviral vectors) has a huge influence on the duration of CAR expression and potential for repeat dosing.

Pursuing oncology + autoimmune is an increasingly popular story given the TAM expansion, but each indication has different development priorities that need to be reconciled. Refractory cancer optimizes for depth and duration of depletion — the disease is lethal and so the goal is durable tumor control. The dream of moving in-vivo approaches into earlier-line autoimmune settings means competing with treatments that would otherwise manage the disease for years. That makes safety, outpatient feasibility and controllability central to the commercial opportunity. While the long-term TAM is potentially massive, the first step will be establishing durable benefit in severe refractory patients to justify earlier-line use.

Big Pharma has made a presence early through M&A: Lilly/Orna ($2.4B), Gilead/Interius ($350M), AstraZeneca/EsoBiotec ($1B), AbbVie/Capstan ($2.1B), BMS/Orbital ($1.5B). Some of these companies (BMS, Gilead) bring deep cell therapy roots, while others (AbbVie, Lilly) built on I&I domain expertise and acquired programs specifically to pursue autoimmune disease. For Lilly and AbbVie, the opportunity is that in-vivo delivery could reduce reliance on bespoke manufacturing infrastructure that defined the prior generation of cell therapy. If these treatments can reach broader autoimmune populations, then I&I development expertise, KOL relationships and delivery IP could be more decisive in determining who wins.